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HLA-B*57 control of HIV involves enhanced CD8+ T cell responses against infected cells,
but extensive heterogeneity exists in the level of HIV control among B*57+ individuals.
Using whole-genome sequencing of untreated B*57+ HIV-1–infected controllers and
noncontrollers, we identified a single variant (rs643347A/G) encoding an isoleucine-to-
valine substitution at position 47 (I47V) of the inhibitory killer cell immunoglobulin-like
receptor KIR3DL1 as the only significant modifier of B*57 protection. The association was
replicated in an independent cohort and across multiple outcomes. The modifying effect of
I47V was confined to B*57:01 and was not observed for the closely related B*57:03.
Positions 2, 47, and 54 tracked one another nearly perfectly, and 2 KIR3DL1 allotypes
differing only at these 3 positions showed significant differences in binding B*57:01
tetramers, whereas the protective allotype showed lower binding. Thus, variation in an
immune NK cell receptor that binds B*57:01 modifies its protection. These data highlight the
exquisite specificity of KIR-HLA interactions in human health and disease.
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Introduction
HIV-1 disease progression is influenced by host genetic factors 
and varies greatly among infected individuals. Polymorphism in 
the HLA class I locus has been consistently shown to associate 
with outcome of untreated HIV-1 infection by both the candidate 
gene approach (1) and GWAS (2, 3). The influence of HLA-B alleles 
is particularly robust, among which HLA-B*57 and -B*27 show 
consistent protective effects (4–8), and HLA-B*35 subtypes are 
associated with accelerated disease progression (9). B*57 is highly 
enriched in rare individuals who maintain undetectable viral loads 
(VLs) (plasma HIV-1 RNA <50 copies/ml) in the absence of antiret-
roviral therapy (10). Up to 50% of these “elite controllers” carry 
B*57 alleles as compared with a frequency of 7% to 8% in noncon-
trollers (11) or the general white population. Notably, however, 
in the absence of antiretroviral therapy, most B*57+ HIV-infected 
individuals fail to control HIV and typically progress to AIDS with 
a temporal range similar to that of individuals without B*57 (8), 
indicating the presence of distinct modifiers of B*57 protection.
The mechanistic role of HLA-B*57 in controlling the virus 
is not fully understood, but data suggest that immune respons-
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predicted functional conse-
quences (e.g., nonsynony-
mous, splice site acceptor/
donor, start/stop loss or gain, 
frameshift variants). Only a 
single variant, rs643347A/G, 
located in the KIR3DL1 gene, 
remained statistically signif-
icant after Bonferroni cor-
rection for multiple testing 
(Supplemental Figure 1). This 
variant results in an isoleucine (rs643347A) to valine (rs643347G) 
aa substitution at codon 47 within the D0 domain of the mature 
KIR3DL1 protein, and rs643347G was associated with elite control 
(P = 2.4 × 10–7, Fisher’s exact test; Table 1). Two additional variants 
within the KIR genomic region, rs1049150 (isoleucine to leucine at 
aa 54 in KIR3DL1) and rs1049215 (threonine to alanine at aa 115 in 
KIR2DL4), both of which are in linkage disequilibrium (LD) with 
rs643347 (r2 = 0.93, D′ = 1, and r2 = 0.76, D′ = 0.99, respectively), 
were also identified, but these did not remain statistically signifi-
cant after correction (Supplemental Figure 1).
In order to validate the WGS results, we analyzed data from 
an independent B*57+ cohort consisting of 297 HIV+ individuals 
with a more lenient definition of control (VL <2,000 viral RNA 
copies/ml of plasma) and 213 noncontrollers (VL >10,000 viral 
RNA copies/ml of plasma) (Supplemental Table 1). This cohort 
had a broader range of clinical phenotypes relative to the extreme 
phenotypes of the initial cohort in which WGS was performed, 
particularly with respect to the controllers (89% elite controllers 
in the WGS cohort vs. <60% in the validation cohort, in which an 
elite controller is defined as having undetectable VLs using stan-
dard assays). KIR3DL1 subtyping was performed in the validation 
cohort and confirmed the association of 47V with significantly 
better HIV control (56.9% in controllers vs. 47.7% in noncontrol-
lers; P = 0.004; Table 1). The weaker effect we observed in the 
validation cohort was consistent with the broader range of clinical 
phenotypes in this cohort relative to the discovery cohort.
Variants encoding aa 2, 47, and 54 have the strongest effects on 
HIV-1 control relative to other KIR3DL1 nonsynonymous variants. 
KIR3DL1 is a highly polymorphic locus that contains many non-
synonymous variants (http://www.ebi.ac.uk/ipd/kir/) that are in 
strong LD with one another. While WGS pointed to aa 47 as having 
the greatest effect on B*57 control of HIV-1, other variants within 
the gene that may not have reached genome-wide significance 
because of poor detection quality could contribute to the effect 
observed with aa 47. We therefore used the pooled data from the 
WGS and validation cohorts to test for effects of each nonsyn-
onymous variant within the KIR3DL1 gene. Homozygotes plus 
heterozygotes of the lower-frequency allele were compared with 
homozygotes of the higher-frequency allele in order to gain power 
when testing rarer allelic variants. Variants encoding aa positions 
2, 47, and 54 are in strong LD (ref. 23 and Supplemental Table 2), 
and thus the effect of each of these 3 aa was comparable (odds ratio 
[OR] = 0.2–0.3, P = 0.003–0.0003). We observed that aa 283 had 
a weak effect (OR = 0.6, P = 0.02), but no other aa variant in the 
KIR3DL1 molecule significantly modified the effect of B*57 on HIV 
control (data not shown). Thus, I47V tags 2 additional coding vari-
es mediated through both acquired and innate mechanisms are 
involved. B*57 binds several immunodominant epitopes located in 
conserved regions of Gag, implicating B*57-restricted CD8+ T cell 
responses in controlling viral replication (12–14). Escape mutations 
within these B*57-restricted epitopes can result in reduced viral 
fitness (15–19). Viral adaptation to host HLA genotypes results in 
escape from cytotoxic T lymphocyte (CTL) responses, and high 
levels of adaptation appear to have profound deleterious effects 
on viral control, even among B*57+ individuals (20). Reduced 
viral fitness does not compensate for the loss of an effective CTL 
response, and HIV controllers with B*57 have significantly lower 
adaptation scores than do B*57 noncontrollers. Nevertheless, CTLs 
from patients with B*57 are more cross-reactive to various HIV epi-
topes after point mutations in these epitopes have occurred relative 
to CTLs from patients with B*08, an allele that is associated with 
more rapid disease progression (21). This observation is supported 
by computational modeling of thymic selection, in which a larger 
fraction of the naive repertoire of B*57-restricted T cell clones is 
specific for HIV relative to that of other alleles, and B*57-restricted 
T cells are more cross-reactive to mutants of targeted epitopes (22), 
possibly impeding viral adaptation in B*57+ individuals.
Here, we identify a nonsynonymous variant in the killer cell 
immunoglobulin-like receptor (KIR3DL1) gene (I47V) that modi-
fies B*57 protection against HIV-1. To our knowledge, this is the 
only locus identified genome-wide that associates with the level 
of B*57 control, and the effect was replicated in an independent 
cohort of B*57+ HIV-1–infected subjects. The protective effect of 
I47V was restricted to the B*57:01 subtype, and no such effect was 
observed for the closely related B*57:03. These 2 allotypes dif-
fer only at positions 114 and 116, located in the E and F pockets, 
respectively, which specify peptide binding, suggesting that differ-
ences in the positioning or sequence of peptides bound to B*57 are 
in part responsible for the protective effect of KIR3DL1 47V.
Results
The KIR3DL1 rs643347G variant is enriched in B*57+ HIV-1–infected 
controllers. We performed whole-genome sequencing (WGS) of 
B*57+ controllers (n = 100) and B*57+ noncontrollers (n = 100) 
(Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI98463DS1) in order 
to identify host genetic modifiers of B*57 control of HIV-1. The 
controller group used in the whole-genome study was highly 
enriched for elite controllers (89% with a VL <500 copies/ml). 
Sequence data were of high quality for 187 samples, including 97 
controllers and 90 noncontrollers, allowing for statistical analysis 
of 56,808 variants genome wide that were chosen on the basis of 
Table 1. Allele frequency of rs643347G/A in 2 independent B*57+ cohortsA
WGS, n = 159B Validation, n = 510
rs643347 allele CTR, n (%) NC, n (%) P value CTR, n (%) NC, n (%) P value
G 73 (43.5) 25 (16.7) 2.4 × 10–7 338 (56.9) 203 (47.7) 0.004
A 95 (56.5) 125 (83.3) 256 (43.1) 223 (52.3)
ASingle-variant analysis using Fisher’s exact test. BHigh-quality sequence data for I47V were available for 159 of the 
187 samples that were included in the genome-wide analysis.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 9 0 5jci.org   Volume 128   Number 5   May 2018
ml plasma), all of whom were B*57+ (Supplemental Table 1). The 
47VV genotype was strongly associated with protection relative to 
47II (OR = 0.2, P = 4 × 10–4; Figure 1 and Supplemental Table 4), 
and the effect appeared to be primarily codominant (P for trend = 
0.001), as 47IV tended to be less protective than 47VV (though not 
significantly) and more protective than 47II (P = 0.04).
The protective effect of KIR3DL1 I47V is apparent when taking into 
consideration alternative outcome measures. We next used a mixed 
linear-effects model to estimate the effect of copy numbers of 
KIR3DL1 47V on longitudinally measured HIV VL and CD4 counts, 
adjusting for allelic effects of HLA-A, HLA-B, and HLA-C and 
the post-enrollment timing of VL measurements. The data were 
analyzed for all subjects combined, for those who were HLA-B 
Bw4+/B*57–, and for B*57-only subjects, for whom KIR3DS1 and 
KIR3DL1*004 were taken into account by being coded as random 
variables (Supplemental Table 1). Consistent with the above results, 
the strongest effect on longitudinal VLs was seen in B*57+ individu-
als, for whom increasing copy numbers of KIR3DL1 47V were associ-
ated with a significantly lower VL (–0.14 log10 copies/ml per KIR3DL1 
47V allele, P = 4.9 × 10–18; Table 2). The protective effect of 47V was 
also observed when considering the mVL (–0.18 log10 copies/ml per 
KIR3DL1 47V allele, P = 6.3 × 10–4) and CD4+ T cell counts, a marker 
of immunopathology due to HIV infection (increase of 24.88 cells/
μl per KIR3DL1 47V allele, P = 1.5 × 10–6; Table 2). In stark contrast, 
there was a significant detrimental effect of increasing copy num-
bers of KIR3DL1 47V among Bw4+/B*57– subjects, suggesting overt 
differential consequences attributable to the fine specificity of KIR-
HLA allotypic interactions on NK cell function.
ants, and although I47V appears to be the most statistically robust, 
any 1 or combination of the 3 aa variants at positions 2, 47, and 54 
may be responsible for modulating B*57 protection against HIV-1.
Genotypes encoding KIR3DL1 aa 47 (I47V) act in a codominant 
fashion to impact HLA-B*57 control of HIV-1. Our initial analyses 
of I47V considered allelic (rather than genotypic) frequencies of 
47I versus 47V (Table 1), and samples carrying only 1 functional 
copy of KIR3DL1 (i.e., those samples in which the other haplotype 
carried either the activating KIR3DS1 or KIR3DL1*004, an allele 
that is not expressed on the cell surface) or no copies of function-
al KIR3DL1 were included in the analyses. KIR3DL1 allele fre-
quencies are shown in Supplemental Figure 2 and Supplemental 
Table 3. As KIR3DL1*004 does not bind B*57 expressed on target 
cells (24, 25), we reasoned that this allele would be functionally 
irrelevant in the analyses performed herein. Furthermore, both 
KIR3DS1 and KIR3DL1*004 may actually confound our results, 
since both have been associated with protection in HIV cohorts 
previously (albeit not in combination with B*57 specifically) (26, 
27). In order to eliminate any potential confounding effect of 
KIR3DS1 and KIR3DL1*004 on the modulation of B*57 protection 
against HIV, we excluded subjects with these 2 alleles and limited 
the genotypic analyses to subjects with 2 copies of KIR3DL1 (i.e., 
those with only a single copy or >2 copies of KIR3DL1 were exclud-
ed), since variable gene copy numbers might also influence our 
analysis (28). We then tested the 3 strict genotypes of I47V (i.e., 
VV, IV, and II) for their frequencies among controllers (mean VL 
[mVL] <2,000 viral RNA copies/ml plasma) as compared with 
frequencies in noncontrollers (mVL >10,000 viral RNA copies/
Figure 1. Influence of KIR3DL1 aa 47 on HIV control in HLA-B*57+ individuals. Only individuals with 2 expressed KIR3DL1 alleles were included in the 
analysis. Individuals with KIR3DS1, KIR3DL1*004 (1 or 2 copies), and KIR3DL1+/– (i.e., KIR3DL1/S1 missing on 1 haplotype) were excluded. Statistical analysis 
was performed using logistic regression. CTR, HIV controllers (n = 188); NC, noncontrollers (n = 136). The numbers above the bars denote the number of 
individuals in each group.
Table 2. Effect of KIR3DL1 I47V on various outcomesA
Outcome measure n (II/IV/VV) EffectB (linear estimate) SE P value
All Longitudinal log10VL 3,865 (1,309/1,800/756) 0.003 0.008 0.69
HLA-B Bw4+/B*57– Longitudinal log10VL 2,022 (659/958/405) 0.09 0.012 2.2 × 10
–13
B*57+ Longitudinal log10VL 674 (238/306/130) –0.14 0.016 4.9 × 10
–18
B*57+ mVL 674 (238/306/130) –0.18 0.05 6.3 × 10–4
B*57+ Longitudinal CD4+ T cell count 588 (208/272/108) 24.88 4.13 1.5 × 10–6
AHLA-A, -B, and -C alleles, timing of VLs measurements, as well as the presence of KIR3DL1*004 and KIR3DS1 were taken into account by being coded as 
random effects for all analyses using a mixed linear-effects model. BEffect estimates denote the effect of each additional 3DL1 47V as an additive effect.
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interface (Supplemental Figure 
3A), we hypothesized that these 
positions would not directly affect 
the binding affinity of the KIR3DL1 
receptor on NK cells. Nevertheless, 
to better understand how polymor-
phisms at positions 2, 47, and 54 
impact recognition of the peptide–
HLA-B*57:01 complex, we initially 
used surface plasmon resonance 
(SPR) to compare direct 1:1 bind-
ing of a number of B*57:01-pep-
tide complexes with KIR3DL1*015 
(2V/47V/54L) or KIR3DL1*001 and 
KIR3DL1*005 (2M/47I/54I). In spite of the clearly opposing effects 
of KIR3DL1*015 and KIR3DL1*001 on modification of B*57:01 
protection (Figure 3A), these 2 KIR allotypes bound to B*57:01 with 
similar affinity, but with slightly weaker affinity than binding to 
KIR3DL1*005. This confirmed that there was no strict correlation 
between 47V-associated protection and a higher affinity of 47V 
KIR3DL1 allotypes for B*57:01, at least with the peptides tested via 
SPR (Supplemental Figure 3, B–E, and Supplemental Table 5).
Since we did not observe differences in affinity with SPR, 
positions 2, 47, and 54 might alter the avidity of KIR3DL1 through 
receptor clustering. On the basis of the crystal packing of the 
KIR3DL1-B*57:01 complex (33), we constructed a structural mod-
el of KIR3DL1 (Supplemental Figure 3A), in which positions 47 
and 54 are part of an extensive interface incorporating the α2 and 
α3 domains of neighboring HLA. This region is strictly conserved 
in B*57 allotypes and highly conserved across HLA alleles (IMGT/
HLA database: https://www.ebi.ac.uk/ipd/imgt/hla/). In this 
model, each KIR3DL1 molecule thus makes contact with 2 HLA 
molecules to form higher-order oligomers (i.e., clustering).
To further probe multimeric interactions between KIR3DL1-
HLA, we assessed the binding of HLA-B*08:01 (negative control) 
and B*57:01 tetramers to 293T cells expressing FLAG-tagged 
KIR3DL1*001 or KIR3DL1*015 (which differ only at positions 2, 
47, and 54) or to mutant KIR3DL1 molecules containing reciprocal 
mutations at each position. Analyses of B*57 tetramer binding to 
cells expressing matched levels of KIR3DL1, as defined by equiv-
alent staining with an anti-FLAG mAb, showed increased binding 
to KIR3DL1*001 compared with binding to KIR3DL1*015 (Figure 
3). Mutation of position 47 in the context of either KIR3DL1*001 or 
KIR3DL1*015 had little impact on tetramer binding, whereas muta-
tion of residue 54 resulted in an intermediate phenotype, subtly 
changing binding of the B*57 tetramer to both KIR3DL1*001 and 
KIR3DL1*015. In contrast, substitution of M with V at position 2 of 
KIR3DL1*001 resulted in impaired binding, similar to that observed 
for KIR3DL1*015, but the reciprocal mutation in KIR3DL1*015 
had no effect, suggesting that its effect was dependent on the pres-
ence of 47I and/or 54I. Taken together, these data suggest that the 
dimorphisms at these 3 positions have little direct effect on affinity, 
consistent with their location distant from the ligand-binding site of 
KIR3DL1 (Supplemental Figure 3A); yet in the context of multiva-
lent binding, these residues may act coordinately in a manner that 
impacts the recognition of B*57, possibly affecting receptor cluster-
ing and thereby affecting NK cell function.
The effect of KIR3DL1 I47V variation on HIV control is spe-
cific to B*57:01 and requires surface-expressed KIR3DL1 alleles. 
In an attempt to further explore the specificity of the KIR3DL1 
I47V–B*57 interaction, we next analyzed individual B*57 subtypes. 
This analysis was restricted to B*57:01 and B*57:03, because we 
had insufficient power to determine a reliable effect estimate for 
B*57:02 and B*57:04 (n = 28 and 3, respectively). Reminiscent of 
abacavir specificity for B*57:01 (29–32), the protective effect of 
KIR3DL1 I47V on the longitudinal VL was only observed among 
individuals with B*57:01 (–0.36 log10 copies/ml, P = 1.7 × 10–67; 
Table 3), with no effect seen for B*57:03 (0.01 log10 copies/ml, 
P = 0.16). We observed similar results for longitudinal CD4+ T cell 
counts (90.9 cells/μl, P = 1.7 × 10–43 for B*57:01 vs. 20 cells/μl, P = 
0.06 for B*57:03; Table 3), as well as for the comparison of control-
lers versus noncontrollers (B*57:01 VV vs. II: OR = 0.2, P = 0.001; 
B*57:03 VV vs. II: OR = 0.4, P = 0.25; data not shown).
We estimated the effect of each common KIR3DL1 allele (see 
Supplemental Table 3) on longitudinal viremia among B*57+ indi-
viduals in order to compare association patterns between B*57:01 
and B*57:03 as a function of KIR3DL1 subtype. The 47V alleles 
KIR3DL1*015 and KIR3DL1*002 were associated with significant-
ly lower VLs, whereas the 47I allele KIR3DL1*001 was associated 
with a higher VL among B*57:01 subjects (Figure 2A). KIR3DL1*015 
(2V/47V/54L) and KIR3DL1*001 (2M/47I/54I) have identical aa 
sequences, except for positions 2, 47, and 54 (Figure 2C), and it 
is therefore notable that these 2 alleles modify B*57:01 effects on 
HIV in opposite directions. In B*57:03+ subjects, a distinct pattern 
of association was observed, in which KIR3DL1*002 (47V) was 
associated with a high VL and KIR3DL1*001 (47I) with protection 
(Figure 2B). KIR3DL1*004 (47I allele), which is not expressed at 
the cell surface (25), showed no effect, which is consistent with the 
protective effect of 47V being specific to KIR3DL1 (as opposed to 
it tagging variants in neighboring genes) and requiring a surface- 
expressed KIR3DL1 in conjunction with B*57:01. B*57:01 and 
B*57:03 differ by only 2 aa: 114 (D vs. N, respectively) and 116 (S 
vs. Y, respectively), located in the E and F pockets, respectively, of 
the peptide-binding groove, which are key pockets for determin-
ing which peptides will bind (30). These data raise the possibili-
ty that the presentation of peptide bound to B*57 molecules may 
determine, at least in part, whether or not 47V modulates protec-
tion conferred by the specific B*57 subtype.
The effect of KIR3DL1 I47V on ligand binding. Given the distal 
location of positions 2, 47, and 54 to the peptide-HLA–binding 
Table 3. Effect of KIR3DL1 I47V on log VL and CD4+ T cell counts in individuals with B*57:01  
and B*57:03A
Genotype n Outcome EffectB (linear estimate) SE P value
B*57:01+ 398 Longitudinal log10 VL –0.36 0.02 1.7 × 10
–67
B*57:03+ 245 0.01 0.03 0.16
B*57:01+ 383 Longitudinal CD4+ T cell count 90.9 6.53 4.8 × 10–43
B*57:03+ 241 20 9.4 0.06
AHLA-A, -B, and -C alleles, timing of VL measurements, as well as the presence of KIR3DL1*004 and KIR3DS1 
were taken into account by being coded as random effects for all analyses using a mixed linear-effects model. 
BEffect estimates denote the effect of each additional 3DL1 47V as an additive effect.
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Stronger KIR3DL1-mediated inhibition of NK cells in the pres-
ence of HLA-B Bw4 subtypes that have isoleucine at position 80 
(Bw4-80I) relative to those with threonine (Bw4-80T) (37) was the 
first indication of differential binding of KIR3DL1 to its various 
HLA-Bw4 ligands. Additional nuances in differential KIR3DL1–
HLA-B interactions have since been reported, including recent 
studies suggesting a variation in surface expression of both receptor 
and ligand (38) as well as a differential binding capacity of specif-
ic KIR3DL1 allotypes to certain HLA-Bw4 ligands (24, 25, 38–40). 
High cell-surface-expression alleles of KIR3DL1 in combination 
with HLA-B Bw4-80I alleles, which include B*57, were previous-
ly shown to be protective against HIV-1 (27). While there is over-
lap between 47V and high-expression alleles (and between low- 
expression alleles and 47I) (Supplemental Figure 2), the groupings 
are not identical. Most notably, KIR3DL1*001 is a high-expression 
47I allele, and KIR3DL1*007 is a low-expression 47V allele. The 
modifying effect of 47V appears to be B*57:01 specific, whereas the 
effect of high/low KIR3DL1 expression was observed for HLA-B 
Bw4-80I alleles overall. In light of our previous findings regarding 
KIR3DL1 expression levels (27), as well as the protective effect of 
KIR3DS1 in combination with HLA-B Bw4-80I (which includes 
B*57) (26), we performed a multivariate mixed linear-effects anal-
ysis to determine the relative effects of KIR3DL1 aa47, KIR3DL1 
Discussion
Superior HIV control among the B*57+ subjects as a function of 
enhanced CTL responses against B*57-restricted epitopes and the 
T cell receptors that recognize the complex (12–14, 21, 34) cannot 
explain the sizeable heterogeneity in HIV disease progression 
observed in the B*57+ subjects. Analyses of our European Ameri-
can seroconverter cohorts showed that 50% of B*57+ subjects had 
progressed to AIDS 1993 (1993 definition of the US Centers for 
Disease Control and Prevention) (35) by 11.2 years after infection 
compared with 71% of B*57– subjects (data not shown). B*57+ con-
trollers and noncontrollers present the same immunodominant 
B*57-restricted HIV gag epitopes, and escape mutations can occur 
in both groups (36). Thus, modifiers of B*57 responses against HIV 
probably affect its efficacy.
We used a genome-wide approach to examine genetic variants 
that may enhance or diminish B*57 protection among controllers 
versus noncontrollers and identified only a single variant encod-
ing an isoleucine-to-valine change at position 47 in the KIR3DL1 
molecule. The association was conclusively verified in a second 
cohort of viremic controllers compared with noncontrollers (P 
= 0.004) and in an analysis of longitudinal VLs and CD4+ T cell 
counts (P = 4.9 × 10–18 and 1.5 × 10–6, respectively), with each addi-
tional 3DL1 47V as an additive effect.
Figure 2. Effect of individual KIR3DL1 alleles on longitudinal HIV viremia in subjects with B*57 subtypes. A mixed linear-effects model adjusting for all 
HLA-A, -B, and -C alleles and post-enrollment timing of measurements was used to estimate the effect of each KIR3DL1 allele for groups including individ-
uals with (A) B*57:01 only and (B) B*57:03 only. 47I alleles are shown in red, and 47V alleles are shown in blue. The horizontal bars represent a 95% CI. The 
size of the black dots was scaled according to the frequency of each allele. Alleles with estimates that did not cross the line, which represents no change 
in VL (0), are significant. (C) Extracellular domain aa alignment of the KIR3DL1 alleles tested in A and B (http://www.ebi.ac.uk/ipd/kir/). Red = D0, green = 
D1, blue = D2. Positions 2, 47, and 54 are highlighted in yellow.
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expression levels, and KIR3DS1 on HIV viremia in B*57:01+ and 
B*57:03+ subjects (see Supplemental Table 6). For B*57:01, we 
found that the strongest and most significant KIR3D effect involved 
KIR3DL1 47V (effect estimate = –0.53 for each additional 47V copy; 
P = 9 × 10–86). Nevertheless, some B*57:01+ individuals with the pro-
tective KIR3DL1 47V allele were noncontrollers, supporting a mod-
el in which a complex set of host and viral factors determine dis-
ease outcome among B*57:01+ subjects, with KIR3DL1 47V being 
one of these factors. Variation in other regions of the genome that 
are difficult to decipher by GWAS, such as genes encoding T cell 
receptors, immunoglobulins, and the leukocyte receptor complex 
(which includes the KIR genes), along with viral, environmental, 
and behavioral factors, are likely to affect the ability of B*57+ sub-
jects to control HIV. Overall, the impact of KIR3DL1 variation on 
HIV outcome is multifactorial and characterized by fine specifici-
ty between KIR3DL1 allotypes and their HLA-B + peptide ligands, 
which likely affects the NK cell response to HIV-infected cells.
Two common alleles containing 47V, KIR3DL1*015 and 
KIR3DL1*002 confer strong protection in combination with 
B*57:01, and these KIR alleles probably account, in large part, for 
the observed effect of 47V among B*57:01+ subjects (Figure 2). 
KIR3DL1*015 and KIR3DL1*002 differ only at a single aa in the 
D2 domain, which is unlikely to alter the interaction with B*57:01. 
However, KIR3DL1*015 and KIR3DL1*001, which differ only at 
aa 2, 47, and 54 (Figure 2C), convincingly showed opposite modi-
fying effects on B*57:01. This genetic epidemiological observation 
may be related to the reduction in binding of B*57:01 tetramers 
to KIR3DL1*015 relative to KIR3DL1*001 and KIR3DL1*005 (ref. 
41 and Figure 3). Perhaps HIV Nef downregulation of HLA-B, in 
combination with reduced binding of KIR3DL1*015 to B*57:01, 
results in attenuated inhibitory signaling through this KIR, 
resulting in greater NK cell activation against HIV-infected tar-
gets. Both HLA-B*57:01 and B*57:03 bind KIR3DL1 with high 
affinity as assessed by their binding to bead-immobilized HLA 
class I allotypes. Indeed, HLA-B*57:01 has been the strongest 
KIR3DL1-binding HLA allotype, irrespective of the KIR3DL1 allele 
tested, and B*57:03 has typically been in the top 10% of allotypes 
(40). As such, they would both be expected to license KIR3DL1+ 
NK cells effectively, but there are no data to confirm wheth-
er the small incremental increase in KIR3DL1 binding shown in 
our study results in a difference in the number of licensed cells 
between B*57:01+ and B*57:03+ individuals.
In spite of differential tetramer binding to KIR3DL1*001 (47I) 
versus KIR3DL1*015 (47V), we did not detect clear differences in 
binding affinities of KIR3DL1*001 or KIR3DL1*015 for B*57:01 by 
SPR (Supplemental Figure 3, B–E, and Supplemental Table 5). As 
these experiments were conducted with a limited number of pep-
tides, any differences in affinity for B*57:01 conferred by positions 
2, 47, and 54 may be apparent only across a diverse repertoire of 
peptides. It is also possible that positions 2, 47, and 54 may impact 
receptor clustering on NK cells and thus the avidity of the interac-
tion. Differences in receptor clustering on the cell surface, a surro-
gate for signaling potential, may thereby alter the NK cell response 
to HIV-infected targets. Positions 2, 47, and 54 also flank sites in 
D0 (positions 5, 31, and 32) that have been shown to be under pos-
itive natural selection (42), and there are data that further support 
the importance of these 3 positions in ligand binding (23).
Individually, the impact of mutations at positions 2, 47, or 54 
of KIR3DL1 differed markedly, but each was dependent on the 
variants present at the other 2 positions (Figure 3), indicating that 
any potential effect of a given polymorphism is dependent on the 
structural framework of the D0 domain. Furthermore, mutagen-
esis experiments indicate that D0 is important for folding and 
cell-surface expression of KIR3DL1 (43) and contributes to the 
binding avidity of HLA ligands (44). Limited aa differences across 
KIR ligands can also impact the consequences of their interac-
tions. B*57:01 and B*57:03 differ by 2 aa (positions 114 and 116) 
in the peptide-binding groove, and although their peptide-binding 
Figure 3. HLA-B*57:01/LF9 tetramer bind-
ing to KIR3DL1 variants. 293T cells were 
transfected with FLAG-tagged KIR3DL1*001, 
KIR3DL1*015, or mutants and stained with 
HLA-B*57:01/LF9 or HLA-B*08:01/FLR tetram-
ers (350 ng each). (A) MFI of HLA-B*57:01/
LF9 binding to FLAG-positive sections from a 
representative experiment (performed in tripli-
cate). ****P < 0.0001, by ANOVA with Tukey’s 
multiple comparisons test. Data represent the 
mean ± SEM. (B) The MFI of tetramer staining 
on FLAG-positive sections was normalized 
to HLA-B*57:01/LF9 binding to KIR3DL1*001 
across 4 independent transfection experi-
ments. Data represent the mean ± SEM.
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motifs are nearly indistinguishable, they do show some differences 
in peptide preference (HIV Molecular Immunology Database: hiv.
lanl.gov), peptide positioning and presentation, and immune pres-
sure on the virus. Crystal structures of HLA-B*57:01 and B*57:03 
have been previously determined by us and other groups (29, 30, 
33, 45). Positions 114 (aspartate to asparagine) and 116 (serine to 
tyrosine) lie in the floor of the peptide-binding groove and hence 
cannot directly contact KIR3DL1. Rather, they alter the architec-
ture and charge of the E and F pockets. Thus, they probably affect 
the repertoire of peptides that can bind each allotype and the way 
in which peptides are positioned in the binding groove, thereby 
differentially altering the recognition of these peptide-MHC com-
plexes by any given KIR3DL1 subtype. Recent data also indicate 
that KIR3DL1 polymorphisms contribute to differential bind-
ing preferences for HLA class I allotypes, with B*57:01 showing 
better binding than B*57:03 (40). These distinctions profoundly 
influence the modifying effects of specific KIR3DL1 alleles on 
the closely related B*57:01 versus B*57:03 alleles (Figure 2) and 
emphasize the granularity of KIR3DL1–HLA-B interactions.
Methods
Subjects. Data from a total of 3,878 HIV-1–infected individuals, including 
818 B*57+ individuals (n = 482 whites, n = 270 blacks, n = 40 other, n = 26 
unknown), were used in this study. The B*57+ individuals included 614 
men (75.1%), 150 women (18.3%), 4 transgender individuals (0.5%), 
and 50 individuals of unknown gender (6.1%). In the discovery phase, 
WGS was performed on 100 B*57+ HIV+ controllers (n = 90 whites, 
n = 10 other/unknown) and 100 B*57+ HIV+ noncontrollers (n = 97 
whites, n = 3 other/unknown). Controllers were antiretroviral therapy– 
naive (ART-naive) individuals with at least 3 VL measurements (most 
individuals had >6), the majority of which had fewer than 500 copies of 
HIV-1 RNA/ml of plasma (range = <500–1,681; 89% had <500); CD4+ 
T cell counts above 400/mm3; and a duration of infection of more than 
4 years. Noncontrollers included individuals with at least 1 VL above 
10,000 copies/ml of plasma and at least 1 CD4+ T cell count below 
500/mm3 (most had multiple CD4 counts of <500/mm3).
The numbers for B*57+ individuals used in each outcome analysis 
are shown in Supplemental Table 1. For the mixed linear-effects analy-
ses, a total of 36,074 longitudinal VL measurements were available for 
3,865 individuals of all HLA-B genotypes (individuals with ≥1 VL mea-
surement), including 17,548 measurements for 674 B*57+ individuals. 
A total of 16,050 CD4 counts were available for 588 B*57+ individuals. 
There was an overlap of 566 B*57+ subjects between the categorical 
analyses (n = 710) and the mixed linear-effects analyses (n = 674).
The subjects in this study were enrolled into 1 of 8 study cohorts: 
the Multicenter AIDS Cohort Study (MACS) (46); the AIDS linked to 
the Intravenous Experience (ALIVE) cohort (47); the Massachusetts 
General Hospital (MGH) controller cohort (http://hivcontrollers.org/
hivcontrollers/); the Study on the Consequences of Protease Inhibi-
tor Era (SCOPE) (48); the AIDS Clinical Trial Group (ACTG) cohort 
(https://actgnetwork.org); the Swiss HIV Cohort Study (SHCS) (http://
www.shcs.ch); the U.S. military HIV Natural History Study (USMNHS) 
(www.idcrp.org); and the NIAID long-term nonprogressor cohort (49).
WGS. WGS data were generated for 191 of 200 B*57+ samples on 
the Illumina HiSeq 2000 platform using 100-bp paired-end reads. 
Samples were sequenced to an average depth of 36× coverage (range 
29.9–53.4×). PCR duplicates were removed using Picard Tools, version 
1.59, and unique reads were aligned to build 37 of the human genome 
reference sequencing using BWA, version 0.5.10. Sequence variants 
were identified using GATK-1.6-11 and annotated using snpEff-3.3.
Two samples were found to have discordances between their 
self-declared gender and that inferred from the sequencing data using 
the estimated X/Y chromosome ratios and were excluded from further 
analysis. Two additional samples were found to be duplicates based 
on 100% identity using a panel of 4,000 common variants to test for 
cryptic relatedness between samples and were also excluded. Thus, 
187 samples were included in the genomewide analysis, of which 97 
were from controllers and 90 were from noncontrollers.
Associations between genetic variants and controller or noncon-
troller status were examined using both single-variant tests and gene-
based collapsing analyses of rare functional variants (minor allele fre-
quency <5%) using the Analysis Tool for Annotated Variants (ATAV) 
software package (https://github.com/igm-team/atav). Significance 
scores were determined using Fisher’s exact test adjusted for multi-
ple testing using a Bonferroni correction for the number of variants or 
genes included in each analysis.
HLA and KIR genotyping. HLA genotyping was performed either 
by PCR–sequence-specific oligonucleotide probing (PCR-SSOP), 
PCR–sequence-based typing (PCR-SBT) using the Sanger sequencing 
technology recommended by the 13th International Histocompatibil-
ity Workshop (http://www.ihwg.org), or next-generation sequencing 
using the Roche 454 platform (50). KIR genotyping for the presence 
or absence of KIR genes was performed by PCR–sequence-specific 
priming (PCR-SSP) (51), followed by KIR3DL1 sequencing using gene- 
specific primers (52). Allele frequencies are shown in Supplemental Fig-
ure 2 and Supplemental Table 3. These frequencies are comparable with 
those seen in the general population (http://www.allelefrequencies.
net/default.asp). The KIR3DL1 copy number was determined using a 
quantitative real-time PCR assay as previously described (28). In cases 
in which DNA was not available, the copy number was imputed on the 
basis of the overall KIR profile and the results of KIR3DL1 subtyping.
Protein expression and purification. The HLA-B*57:01 and β2- 
microglobulin genes were subcloned into the pET-30 expression vec-
tor and expressed separately into inclusion bodies in E. coli. The HLA 
complex was refolded in the presence of the ISPRTLNAW (IW9, HIV-1 
gag), KAFSPEVIPMF (KF11, HIV-1 gag), QASQEVKNW (QW9, HIV-1 
gag), and LSSPVTKSF (LF9, self) peptides and purified as described 
previously (53). KIR3DL1*001, KIR3DL1*005, and KIR3DL1*015 (res-
idues 1–299) were subcloned into the pFastBac insect expression vec-
tor with N-terminal 6xHis and secretion tags. KIR3DL1 was expressed 
from Hi-5 insect cells (Invitrogen, Thermo Fisher Scientific) and 
secreted into the culture media. The protein was purified as described 
previously (33) and then concentrated in a buffer composed of 10 mM 
Tris (pH 8.0) and 300 mM NaCl, prior to use in SPR experiments.
SPR. SPR experiments were used to measure the affinities of 
KIR3DL1*001, KIR3DL1*005, and KIR3DL1*015 for HLA-B*57:01 
presenting the HIV-1 gag epitopes IW9, KF11, and QW9 and the 
self-epitope LF9. SPR experiments were conducted on a Biacore 3000 
instrument at 298 K. A CM5 chip was used to immobilize the anti-
HLA mAb W6/32 (generated in-house, ref. 54) via amine coupling. 
HLA-B*57:01-peptide complexes were then captured on the chip by 
binding to W6/32 to a surface density of approximately 700 response 
units. KIR3DL1*001 (2.25–350 μM), KIR3DL1*005 (2.25–350 μM), 
and KIR3DL1*015 (1.56–200 μM) were injected over the chip at a 
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ty Bloomberg School of Public Health (Lisa Jacobson, Gypsyamber 
D’Souza), UM1-AI35043. The MACS is funded primarily by the 
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AI069477, AI027675, AI073961, AI069474, AI069432, AI069513, 
AI069423, AI050410, AI069452, AI69450, AI054907, AI069428, 
AI045008, AI069495, AI069415, AI069556, AI069484, 
AI069424, AI069532, AI069419, AI069471, AI025859, AI069418, 
AI050409, AI069501, AI069502, AI069511, AI069434, 
AI069465, AI069494, AI069472, AI069470, AI046376, 
AI072626, AI027661, AI034853, AI069447, AI032782, AI027658, 
AI27666, AI058740, AI046370, TR000445, RR00051, RR00046, 
RR025747, RR025777, RR024160, RR024996, and RR024156. 
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Gilead Sciences, and GlaxoSmithKline provided study medications. 
DWH is also supported by NIH grants AI077505, AI110527, and 
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Research Council of Australia, the Anti-cancer Council, the Austra-
flow rate of 5 μl/min in a buffer composed of 10 mM HEPES-HCl (pH 
7.4), 150 mM NaCl, and 0.005% surfactant P20. The response to the 
W6/32-only control flow cell was subtracted from the responses to 
HLA-B*57:01–peptides. Equilibrium data were analyzed using Graph-
Pad Prism Version 7. All data are representative of 2 independent 
experiments, with each experiment conducted using duplicate sam-
ples. Data represent the mean ± SEM.
Tetramer-binding assay. pEF6.FLAG-tagged KIR3DL1*001 and 
KIR3DL1*015 constructs (41) were mutated at residues 2, 47, and 54 
via site-directed mutagenesis. pEF6.KIR3DL1*001 and KIR3DL1*015 
were transfected into 293T cells using FuGENE 6 Transfection 
Reagent (Promega) according to the manufacturer’s instructions, and 
KIR3DL1 surface expression was confirmed via staining with NKB1-
FITC (clone DX9; BD Pharmingen) after 48 hours. Transfected 293T 
cells (originally purchased from ATCC) were stained with 350 ng/test 
tetrameric HLA-B*57:01/LF9 or HLA-B*08:01/FLR conjugated with 
phycoerythrin-streptavidin (PE-SA) and incubated at room tempera-
ture for 30 minutes. Cells were washed and stained with anti–FLAG-
APC (clone L5; BioLegend) before flow cytometric analysis.
Statistics. SAS 9.2 (SAS Institute) or R 3.3.1 (The R Foundation) was 
used for data management and statistical analyses. PROC FREQ was 
used to compute frequencies on categorical variables. PROC LOGIS-
TIC was used to calculate odds ratios and 95% CIs. These analyses 
were performed with combined white, black, and other races/ethnic-
ities (Hispanic/Latino, Asian), adjusting for race. Statistical signifi-
cance refers to 2-sided P values of less than 0.05.
Analyses of the longitudinal VLs and CD4+ T cell counts were per-
formed using the lmer function in R. We allowed for random effects 
due to each HLA-A, HLA-B, and HLA-C allele (or where modified, as 
specified in Results), the post-enrollment timing of measurements, 
and a correction for diploid HLA allele coding. Several alternative out-
comes were tested, including the log10-transformed HIV VL at each 
time point, a geometric mean HIV VL (mVL) of all time points, and the 
CD4+ T cell count at each time point. Likelihood ratio P values were 
calculated using the ANOVA function in R in order to compare nested 
models fit under a maximum likelihood scenario. The P values report-
ed were not adjusted for multiple comparisons.
Study approval. This study was reviewed and approved by the 
protocol review office of the NCI Office of Human Subjects Research 
Protections (OHSRP) in Bethesda, Maryland. Informed consent was 
obtained at the study sites from all individuals prior to their participa-
tion in the study.
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